scholarly journals Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique

2008 ◽  
Vol 7 (1) ◽  
Author(s):  
Sonia Enosse ◽  
Pascal Magnussen ◽  
Fatima Abacassamo ◽  
Xavier Gómez-Olivé ◽  
Anita M Rønn ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Line Treatment ◽  
First Line ◽  
Sulphadoxine Pyrimethamine ◽  
First Line Treatment

scholarly journals Decline in Sulfadoxine-Pyrimethamine-Resistant Alleles after Change in Drug Policy in the Amazon Region of Peru

2007 ◽  
Vol 52 (2) ◽  
pp. 739-741 ◽  
Author(s):  
Zhiyong Zhou ◽  
Sean M. Griffing ◽  
Alexandre Macedo de Oliveira ◽  
Andrea M. McCollum ◽  
Wilmer Marquino Quezada ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Drug Policy ◽  
Amazon Basin ◽  
Microsatellite Analysis ◽  
Amazon Region ◽  
Common Origin ◽  
Line Treatment ◽  
Peruvian Amazon ◽  
First Line ◽  
First Line Treatment

ABSTRACT The frequency of alleles with triple mutations conferring sulfadoxine-pyrimethamine (SP) resistance in the Peruvian Amazon Basin has declined (16.9% for dhfr and 0% for dhps compared to 47% for both alleles in 1997) 5 years after SP was replaced as the first-line treatment for Plasmodium falciparum malaria. Microsatellite analysis showed that the dhfr and dhps alleles are of common origin.

scholarly journals Baseline Ex Vivo and Molecular Responses of Plasmodium falciparum Isolates to Piperaquine before Implementation of Dihydroartemisinin-Piperaquine in Senegal

2019 ◽  
Vol 63 (5) ◽  
Author(s):  
Marie Gladys Robert ◽  
Francis Foguim Tsombeng ◽  
Mathieu Gendrot ◽  
Silman Diawara ◽  
Marylin Madamet ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Copy Number ◽  
Ex Vivo ◽  
Line Treatment ◽  
First Line ◽  
Molecular Responses ◽  
Content Type ◽  
Number Variation ◽  
Plasmepsin Ii ◽  
First Line Treatment

ABSTRACT Dihydroartemisinin-piperaquine, which was registered in 2017 in Senegal, is not currently used as the first-line treatment against uncomplicated malaria. A total of 6.6% to 17.1% of P. falciparum isolates collected in Dakar in 2013 to 2015 showed ex vivo-reduced susceptibility to piperaquine. Neither the exonuclease E415G mutation nor the copy number variation of the plasmepsin II gene (Pfpm2), associated with piperaquine resistance in Cambodia, was detected in Senegalese parasites.

Sign in / Sign up

Export Citation Format

Share Document